IGF1R and Patent ductus arteriosus: Simple pharmacological perturbation of reciprocal nodes (e.g., IGF1R, AXL, AKT, etc.)in existing PDA GEMMs will in principle affect all cell types (e.g., tumor cells, PSCs, immune cells) and cannot provide axis-specific information in vivo.